BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
See today's BioWorld
Home
» Cellartis, Novo, Lund University in $125M Diabetes Stem Cell Pact
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Cellartis, Novo, Lund University in $125M Diabetes Stem Cell Pact
Oct. 29, 2008
By
Cormac Sheridan
No Comments
Stem cell science specialist Cellartis AB could earn as much as €100 million (US$125 million) in development and sales milestones from a cell therapy collaboration in diabetes with Novo Nordisk A/S and Lund University in Sweden. (BioWorld Today)
BioWorld